On May 31, 2024, Mr. Panggen Hu, General Manager of Shanghai Turtle Tech Co., Ltd., and Mr. Lifeng Qi, Chairman of Shanghai Focusgen Biotechnology Co., Ltd., formally signed a bilateral strategic cooperation agreement. This partnership signifies a powerful alliance between the two tech companies, dedicated to advancing collaborative innovation in precision medicine, particularly in the field of tumor liquid biopsy.
This cooperation aims to integrate the strengths and resources of both parties in their respective fields, focusing on technological innovation, product development, and market expansion to enhance core competitiveness and drive industry growth.
Naao Biotechnology’s NextCTC third-generation non-antibody dependent nanomicrofluidic circulating tumor cell (CTC) capture device, along with its fully automated microscopic image scanning system, combines leading nanomicrofluidic technology with artificial intelligence recognition algorithms. This enables efficient, non-destructive capture and intelligent identification of circulating tumor cells, meeting the requirements for subsequent experiments such as PCR, FISH, next-generation sequencing, single-cell sequencing, cell culture, and drug sensitivity tests. It is an essential tool for tumor precision medicine. Meanwhile, Turtle Tech has made significant progress in ctDNA-based tumor liquid biopsy technology, with its exponential ultra-multiplex digital PCR technology poised to bring a disruptive revolution in the field of ctDNA tumor liquid biopsy.
CTC detection and ctDNA detection form the dual pillars of tumor liquid biopsy, providing a new perspective for comprehensive tumor assessment through complementary methods. CTC detection captures and analyzes circulating tumor cells, providing direct evidence of tumor cell morphology, function, and molecular characteristics, aiding in the understanding of tumor heterogeneity and dynamic changes. The intact active CTCs captured by NextCTC can directly undergo digital PCR to detect and analyze tumor cell gene expression, mutations, and epigenetics at the molecular level. By analyzing tumor DNA fragments in peripheral blood through CTCs and ctDNA, genomic variations and mutations of the tumor can be revealed, providing critical information for early diagnosis, therapeutic monitoring, and personalized treatment. The combination of these techniques not only provides comprehensive biological information about the tumor but also enables real-time monitoring of tumor progression and therapeutic response, assisting doctors in devising more precise treatment strategies and advancing the development of tumor precision medicine.
Focusgen Biotechnology is a national high-tech enterprise focused on tumor liquid biopsy medical devices and molecular diagnostics. Founded by overseas returnees, it has established strategic partnerships with several international research institutions. As the chairing unit of the Precision Medicine Branch of the National Health Industry Enterprise Management Association, Focusgen Biotechnology has received numerous national-level awards. The company has successfully developed the third-generation circulating tumor cell capture device and associated detection kits, fully automated microscopic image scanners, and various early cancer screening molecular diagnostic kits. Focusgen Biotechnology has built platforms for tumor liquid biopsy, single-cell sequencing, and molecular diagnostics. Adhering to the philosophy of "Precision Diagnosis, Care for Health," Focusgen Biotechnology is committed to becoming a leader in the development of innovative medical products, benefiting human health.
Shanghai Turtle Technology Co., Ltd. is committed to leading the life sciences and molecular diagnostics into the digital era. Having been approved as the National Demonstration Center for Genetic Testing Technology and obtaining the first Digital PCR Metrological Evaluation Certificate, Turtle Technology have introduced a variety of digital PCR systems and was the first in the world to commercialize a digital isothermal system. This marks a comprehensive technological innovation across the entire industrial chain, including genetic testing instruments, chip consumables, Ultra-Multiplex technology, and ultra-high specificity polymerase.
